Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05669365 · ClinicalTrials.gov registry record · NA
The Care Ecosystem Consortium Effectiveness Study
A NA study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 1,227
- Enrollment target
NCT05669365: Completed NA study, sponsored by University of California, San Francisco.
NCT05669365 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 1,227 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (13% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05669365, a NA study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,227 participants
- Enrollment target
Study Summary
The Care Ecosystem is an accessible, remotely delivered team-based dementia care model, designed to add value for patients, providers and payers in complex organizational and reimbursement structures. Care is delivered via the phone and web by unlicensed Care Team Navigators, who are trained and supervised by a team of dementia specialists with nursing, social work, and pharmacy expertise. The evidence base to date suggests that the Care Ecosystem improves outcomes important to people with dementia, caregivers, and payers when delivered in a controlled research environment, including reduced emergency department visits, higher quality of life for patients, lower caregiver depression, and reduced potentially inappropriate medication use (Possin et al., 2019; Liu et al., 2022). The investigators propose a rapid pragmatic trial in 6 health systems currently offering the Care Ecosystem program in geographically and culturally diverse populations. The investigators will leverage technology, delivering care via the phone and web and using electronic health records to monitor quality improvements and evaluate outcomes while maximizing external validity. The investigators will evaluate the effectiveness of the Care Ecosystem on outcomes important to patients, caregivers, healthcare providers, and health systems during the pandemic. By evaluating the real-world effectiveness in diverse health systems that are already providing this model of care, this project will bridge the science-practice gap in dementia care during an unprecedented time of heightened strain on family caregivers, healthcare providers and health systems.
Primary Outcome
The rate of completion of a 10-item, adapted Dementia Management Quality Measurement Set. This count variable has a range of 0 (no dementia quality care elements completed) to 10 (all dementia quality care elements completed).
Interventions
- BEHAVIORAL Care Ecosystem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,227 participants |
| Start Date | 2023-01-17 |
| Est. Completion | 2025-08-15 |
| Phase | NA |
What the finished NCT05669365 record still lists
NCT05669365 is an interventional study that assigns participants to a tested intervention. Its 1,227 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (13% lower).
The record links to 0 conditions, and to 1 intervention - of which Care Ecosystem is the first listed.
NCT05669365 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05669365 about?
NCT05669365 is a clinical study titled "The Care Ecosystem Consortium Effectiveness Study". The Care Ecosystem is an accessible, remotely delivered team-based dementia care model, designed to add value for patients, providers and payers in complex organizational and reimbursement structures. Care is delivered via the phone and web by unlicensed Care Team Navigators, who are trained and sup...
What is the current status of trial NCT05669365?
This trial is currently completed. It is a NA study. The enrollment target is 1,227 participants. The study started on 2023-01-17. Estimated completion is 2025-08-15.
What interventions are being tested in trial NCT05669365?
The interventions under investigation include: Care Ecosystem (BEHAVIORAL).
Who is sponsoring clinical trial NCT05669365?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05669365's enrollment target sits among peer trials
1,227 83rd of 2000 higher than 1,918 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05946044 · 1,230 participants · NA
The Osteoarthritis Prevention Study
- NCT06787937 · 1,230 participants · NA
Communicating About Nicotine Reduction in Cigarettes
- NCT05456841 · 1,232 participants · NA
Empathic Communication Skills (ECS) Training
- NCT06921785 · 1,220 participants · Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI